New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. 

Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no treatments available for these three drug-resistant strains of Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae.

The Swiss biotech’s new antibiotic class, called OMPTA, targets the outer membrane of Gram-negative bacteria, which is usually the main barrier to antibiotics. It has also contributed to the fact that there have been no new antibiotics for Gram-negative bacteria in over 50 years.

The company’s lead antibiotic, murapavadin, is currently in Phase III development, a feat few other developing antibiotics have been able to reach. The drug has shown potent activity when tested against a panel of 785 strains of extensively drug-resistant Pseudomonas aeruginosa in a petri dishMoreover, the drug did not lead to significant antibiotic resistance or cross-resistance with other antibiotics.

Polyphor’s plans to support the development of its antibiotics further by launching an IPO of up to 150M CHF (€127M) in the second quarter of 2018.


Image by Kateryna Kon/Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.